Diagnostic value of cytokeratin-18 as a tumor marker in bladder cancer

Clinical Biochemistry

Volumn 35, Issue 4, 2002, Pages 327-331

  Şekeroĝlu, Mehmet Ramazan ^a   Aydin, Sabahattin ^a   Dülger, Haluk ^a   Yilmaz, Yüksel ^a   Bayrakli, Haşmet ^a   Noyan, Tevfik ^a  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

Bladder cancer; Cytokeratin 18; Tumor marker

Indexed keywords

CYTOKERATIN 8; TUMOR MARKER; KERATIN;

ADULT; ARTICLE; BLADDER CARCINOMA; CALCULATION; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; BLADDER TUMOR; BLOOD; CHEMOLUMINESCENCE; CLUSTER ANALYSIS; COMPARATIVE STUDY; CONTROL GROUP; MIDDLE AGED; PATHOLOGY; SENSITIVITY AND SPECIFICITY;

BLADDER NEOPLASMS; CHEMILUMINESCENCE; CLUSTER ANALYSIS; COMPARATIVE STUDY; CONTROL GROUPS; FEMALE; HUMAN; KERATIN; MALE; MIDDLE AGE; NEOPLASM STAGING; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; CHEMILUMINESCENT MEASUREMENTS; HUMANS; KERATINS; MIDDLE AGED; URINARY BLADDER NEOPLASMS;

EID: 0036597044     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(02)00321-1     Document Type: Article

References (28)

1. Clinical evaluation of cell deoxiribonucleic acid content measured by flow cytometry in bladder cancer
2. Clinical evolution of soluble cytokeratin 19 fragments (CYFRA-21-1) in serum and urine of patients with bladder cancer
3. Cytokeratin 20 as an objective marker of urothelial dysplasia
4. Bladder cancer: State- of the art care
5. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder
6. Detecting human bladder carcinoma cells in voived urine samples by assaying for the presence of telomerase activity
7. Results of multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer
8. Cancer, oncogenes, and growth factors
9. Serum tissue polypeptide antigen (TPA): Monoclonal or polyclonal radio-immunometric assay for the follow-up of bladder cancer
10. Molecular Characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18
11. Cytokeratins in the histological diagnosis of malignant tumors
12. Cytokeratins and tissue polypeptide antigen
13. Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: Re-evaluation of a human tumour marker
14. Serum tissue polypeptide antigen (S-TPA) in bladder cancer as a tumour marker
15. TPA prognostic value in superficial bladder cancer
16. Tissue polypeptide antigen (TPA) as a predictor for genitourinary cancers and their metastases
17. Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer
18. Cytokeratin-19 fragment (CYFRA 21-1) in bladder cancer
19. Expression of cytokeratins in the urinary passages
20. Cytokeratins and transitional epithelium of the bladder. Particular distribution of cytokeratins
21. A more objective staging of advanced prostate cancer. Routine recognition of malignant endocrine structures: The assessment of serum TPS, PSA, and NSE values
22. Tissue polypeptide specific antigen (TPS) as a tumor marker for gynaecologic malignancies-a comparative study with tissue polypeptide antigen (TPA), cancer antigen 125 (CA 125) and squamous cell carcinoma-associated antigen (SCC)
23. Serum markers CASA, CEA, CYFRA 21-1, MSA, NSE, TPA and TPS in lung cancer
24. Flow cytometry study of cytokeratin 18 expression according to tumor grade and deoxyribonucleic acid content in human bladder tumors
25. Urinary tissue polypeptide-specific antigen for the diagnosis of bladder cancer
26. Serum TPS versus TPA in Egyptian bladder cancer patients
27. Quantitative analysis of keratin 18 in the urine of patients with bladder cancer
28. Cytokeratins as serum markers in Egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS